The FDA set a PDUFA target action date of April 28, 2027, for varegacestat in desmoid tumors.
Related to this article
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
R. Lor Randall, MD, FACS, reviews a longitudinal study in osteosarcoma showing a strong correlation between ctDNA status and clinical outcomes such as EFS.
Advertisement
Advertisement
Trending on OncLive
1
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
2
Northwestern Medicine Study Finds Lung Transplant Dramatically Improves Survival for Patients With Terminal Lung Cancer
3
STRIDE Plus TACE With/Without Lenvatinib Improves Responses in Embolization-Eligible HCC
4
Dr Spencer on the Potential Role for In Vivo CAR T-Cell Therapy in Myeloma
5